November 12, 2024 News release BioPorto A/S to Host Third Quarter 2024 Earnings Webcast COPENHAGEN, DENMARK and BOSTON, MA, USA, November 12, 2024 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the ...
News Medical on MSN7h
From crude lysate to purity with high-precision AAV capsid measurement with Bio-Rad's new ddPCR KitOur products and solutions are based on technologies to separate, purify, identify, analyze, and amplify biological materials ...
SEKISUI Diagnostics' microbial CDMO business announces it has completed construction of its £15.7 million ($20.7 million) cGMP capacity expansion at its UK site for clinical-grade drug substance ...
Conference call begins at 4:30 p.m. Eastern time todayMIAMI, Nov. 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: OPK) reports business highlights and financial results for the three and nine months ended ...
Additionally, our collaborations with two of the top 10 pharmaceutical companies and a leading biotech company have yielded ...
Operator Good day, and welcome to the OPKO Health third quarter of 2024 financial results conference call. All participants ...
Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously ...
The "India Diagnostic Labs Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" report has been added to ...
Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes #469 oral presentation Session: 626.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback